4.1 PSA Kinetics, Biomarkers & Risk Assessment

PSA Kinetics, Biomarkers & Risk Assessment

Prostate cancer (PCa) represents the most frequently diagnosed non-cutaneous malignancy in European men and ranks as the third leading cancer-related cause of death in European men. The primary diagnostic challenge in modern uro-oncology is not merely detecting cancer, but accurately discriminating between indolent, slow-growing tumors that will never cause clinical harm and aggressive, clinically significant prostate cancers (csPCa) that require timely definitive intervention.

Achieving this balance requires an understanding of prostate cancer epidemiology, genetic predisposition, prostate-specific antigen (PSA) biology, and advanced secondary biomarkers endorsed by the European Association of Urology (EAU) Guidelines.

---

Epidemiology and Etiological Risk Factors

The development of prostate cancer is driven by a complex interplay of non-modifiable demographic factors and germline genetics:

• Age: The incidence of prostate cancer rises steeply after the age of 50. Autopsy studies reveal microscopic, latent foci of adenocarcinoma in over 30% of men in their 50s and up to 60–70% of men aged 80 years or older.
• Ethnic Ancestry: Men of African ancestry exhibit the highest incidence and mortality rates globally, presenting on average at an earlier age with higher-grade disease and higher PSA levels at presentation, driven by a combination of biological, genomic, and healthcare disparity factors. Conversely, men of Asian descent historically demonstrate the lowest incidence rates.
• Family History: An affected first-degree relative approximately doubles risk; multiple affected relatives and early diagnoses increase suspicion of inherited susceptibility. EAU defines hereditary prostate cancer as ≥3 cases in one family, disease in three successive generations, or ≥2 cases diagnosed before 55. Familial clustering alone does not necessarily meet that definition.
• Germline Genetic Alterations:
  • BRCA2: The most clinically impactful genetic mutation in prostate cancer. Pathogenic BRCA2 variants confer several-fold increased risk, especially for early-onset disease; a UK study estimated an 8.6-fold risk by age 65. Furthermore, BRCA2-mutated tumors demonstrate an aggressive biological phenotype characterized by higher ISUP Grade Groups, early extracapsular extension, lymph node involvement, visceral metastasis, and significantly reduced cancer-specific survival.
  • BRCA1: Confers a more modest risk elevation (~3.8-fold increase in men aged <= 65 years).
  • Mismatch Repair (MMR) Genes / Lynch Syndrome: Pathogenic germline variants in MSH2, MSH6, MLH1, or PMS2 confer an estimated 2- to 3-fold elevated risk of aggressive prostate adenocarcinoma.
  • Other Susceptibility Genes: ATM and CHEK2 participate in DNA-damage responses. HOXB13 encodes a homeobox transcription factor; its G84E variant is also associated with inherited prostate-cancer susceptibility.

---

EAU Guidelines on Early Detection & Risk-Adapted Screening

Mass, unselected, population-wide PSA screening remains unendorsed across Europe due to the substantial risks of overdiagnosis (detecting clinically insignificant tumors) and subsequent overtreatment (urinary incontinence, erectile dysfunction). However, landmark randomized trials—notably the European Randomized Study of Screening for Prostate Cancer (ERSPC)—demonstrated a persistent 20% relative reduction in prostate cancer-specific mortality at 16 years of follow-up in screened cohorts.

To capture the survival benefit of early detection while minimizing harm, the EAU Guidelines advocate for an individualized, risk-adapted early detection strategy for well-informed men with a life expectancy of at least 15 years:

1. Informed Consent & Counseling: Men requesting early detection must receive balanced counseling regarding potential benefits (reduced metastases and mortality) and harms (false-positive biopsies, biopsy sepsis, overdiagnosis of indolent disease).
2. Target Populations for Baseline PSA Testing:
   • Age 50 years: All well-informed men in the general population.
   • Age 45 years: Men of African descent or with a family history of prostate cancer diagnosed before 60.
   • Age 40 years: Men carrying pathogenic BRCA2 germline mutations (supported by findings from the prospective IMPACT trial).
3. Baseline PSA Stratification & Rescreening Intervals:
   • Initially increased risk: PSA >1 ng/mL at age 40 or >2 ng/mL at age 60 supports a two-year retesting interval.
   • Lower initial risk: Retesting can be postponed for up to eight years. Baseline PSA predicts long-term risk; choose the interval with age, family history and overall health.
4. Stopping Criteria: PSA testing should be discontinued in asymptomatic men whose life expectancy is less than 10 to 15 years, as screen-detected indolent or intermediate-risk tumors are highly unlikely to impact survival within that timeframe.

---

Prostate-Specific Antigen (PSA) and Derivatives

Total PSA is a 33-kDa single-chain glycoprotein enzyme (human kallikrein-related peptidase 3, KLK3) synthesized almost exclusively by the secretory columnar epithelial cells of the prostate. Its physiological role is to liquefy the seminal coagulum by cleaving semenogelins. PSA is organ-specific, not cancer-specific.

Serum PSA concentrations can be elevated by non-malignant conditions, including benign prostatic hyperplasia (BPH; generating ~0.3 ng/mL per gram of adenoma), acute or chronic bacterial prostatitis, urinary tract infections, acute urinary retention, transurethral catheterization or instrumentation, recent prostate biopsy (elevations persist for 4–6 weeks), vigorous cycling, and recent ejaculation (transient mild elevations lasting 48 hours). To avoid false-positive elevations, EAU recommends repeating an initially elevated PSA of 3–10 ng/mL in an asymptomatic man with normal DRE, typically after four weeks in the same laboratory/assay and without UTI, ejaculation or manipulation. A suspicious DRE or other high-risk presentation needs its own diagnostic pathway.

Free-to-Total PSA Ratio (%fPSA)

In human serum, PSA circulates in two distinct physical states: free PSA (enzymatically inactive, unbound, representing 5–35% of total serum PSA) and complexed PSA (bound irreversibly to protease inhibitors, predominantly alpha-1-antichymotrypsin [ACT] and alpha-2-macroglobulin). Prostate cancer tissue predominantly synthesizes PSA that readily complexes with ACT, resulting in a decreased proportion of circulating free PSA compared to benign tissue.

In patients presenting with a total PSA in the diagnostic grey zone (4.0 to 10.0 ng/mL) and a non-suspicious digital rectal examination:

• Free/total ratio <0.15 (15%): Raises suspicion compared with a higher ratio; it does not establish cancer or its grade.
• Ratio >0.25 (25%): Suggests lower risk, but does not rule out cancer. Integrate MRI, PSA density, age and family history rather than assigning a universal cancer probability or biopsy decision to either cutoff.

PSA Density (PSAD)

PSA Density represents the ratio of total serum PSA concentration (ng/mL) to prostate gland volume (measured in cubic centimeters or milliliters via transrectal ultrasound [TRUS] or magnetic resonance imaging [MRI]):

$\text{PSAD} = \frac{\text{Total PSA (ng/mL)}}{\text{Prostate Volume (cc)}}$

PSAD corrects for the volumetric contribution of benign transitional zone hyperplasia. A commonly used risk threshold is 0.15 ng/mL/cc, interpreted with the MRI category and other findings:

• PSAD > 0.15 ng/mL/cc: Significantly increases the likelihood of clinically significant prostate cancer. It serves as a major deciding factor for performing biopsy, particularly in men with equivocal multiparametric MRI findings (PI-RADS 3) or those being monitored on active surveillance.
• PSAD <0.10 ng/mL/cc: Suggests lower risk of clinically significant cancer; it does not prove that BPH explains the PSA or exclude malignancy.

PSA Velocity (PSAV) and Doubling Time (PSADT)

• PSA Velocity (PSAV): Reflects the absolute rate of PSA increase over time (ng/mL/year), requiring a minimum of three longitudinal measurements obtained across at least 12 to 18 months. Historically, a PSAV > 0.75 ng/mL/year was considered suspicious.
• PSA Doubling Time (PSADT): Measures the exponential time required for the serum PSA level to double.

---

Novel Pre-Biopsy Blood and Urine Biomarkers

To improve diagnostic accuracy and reduce the burden of negative prostate biopsies in men with total PSA levels between 2.0 and 10.0 ng/mL, several molecular reflex biomarkers have been developed and validated:

Blood-Based Biomarkers

• Prostate Health Index (phi): Combines total PSA, free PSA, and the precursor isoform [-2]proPSA into a single algorithmic index: $\text{phi} = \frac{[-2]\text{proPSA}}{\text{Free PSA}} \times \sqrt{\text{Total PSA}}$ The [-2]proPSA isoform is preferentially expressed in prostate cancer tissue. Higher PHI scores indicate greater risk of clinically significant cancer; cutoff performance depends on the population and desired sensitivity. In one prospective study, a 28.6 cutoff at 90% sensitivity could spare 30.1% of unnecessary biopsies. This is a trade-off, not a guarantee that significant cancer will never be missed.
• 4Kscore Test: A commercially available blood test that measures four kallikrein markers in plasma—total PSA, free PSA, intact PSA, and human kallikrein 2 (hK2)—and combines them with patient age, digital rectal examination findings, and prior biopsy history using a proprietary algorithm. The test generates an individualized percentage risk (0–100%) of finding high-grade (Gleason score >= 7 / ISUP Grade Group >= 2) cancer on biopsy.

Urine-Based Biomarkers

• SelectMDx: A non-invasive urine test performed on post-DRE first-void urine. It measures the mRNA expression levels of two biomarker genes (HOXC6 and DLX1) that are overexpressed in clinically significant prostate cancer, combining these molecular signals with clinical risk factors (age, PSA, PSAD, DRE status, family history). SelectMDx provides an individualized probability of finding ISUP >= 2 cancer on biopsy. Its predictive values depend on the tested population and threshold. EAU considers its added clinical value in the upfront-MRI pathway unclear; a negative result is not a guarantee that biopsy can safely be omitted.
• PCA3 (Prostate Cancer Antigen 3): A prostate-specific, non-coding mRNA transcript that is overexpressed 60- to 100-fold in prostate adenocarcinoma compared to adjacent normal or hyperplastic tissue. Measured in first-catch post-DRE urine, the PCA3 score is calculated as the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. A PCA3 score > 35 indicates elevated cancer probability. PCA3 has been studied and used in the repeat-biopsy setting, but EAU considers its clinical utility for current biopsy decisions unclear.
• ExoDx Prostate (IntelliScore - EPI): A liquid biopsy assay measuring exosomal RNA levels of three genes (ERG, PCA3, and SPDEF) in first-void urine collected without requiring a prior digital rectal examination. The 15.6 threshold has been studied for risk stratification in biopsy-naive men aged ≥50 with PSA 2–10 ng/mL; it is not diagnostic. EAU currently considers ExoDx investigational.

---

Digital Rectal Examination (DRE)

Digital rectal examination evaluates the posterior and posterolateral surfaces of the peripheral zone, which accounts for approximately 70% of prostate cancers. A normal prostate feels smooth, symmetrical, and fibroelastic, with a preserved central sulcus.

Clinical Findings and Pitfalls

• Suspicious Findings: Palpable induration, discrete stone-hard nodules, asymmetrical lobar enlargement, obliteration of the median sulcus, or fixation to the pelvic sidewalls.
• Diagnostic Limitations: DRE has low sensitivity (approximately 50–60%) for early-stage organ-confined tumors. Tumors situated in the anterior peripheral zone, the anterior fibromuscular stroma, or the transition zone are anatomically inaccessible to digital palpation.
• Guideline Pathway: An abnormal DRE warrants MRI, or direct biopsy if extracapsular disease is suspected, even when PSA is below a conventional cutoff. EAU reports that about 18% of cancers are detected by suspicious DRE alone, irrespective of PSA. DRE findings also contribute to clinical staging; integrate the examination with PSA, MRI and the clinical context when deciding on tissue sampling.

---

Clinical Prostate Biomarkers Comparison